DrugRisk Center: Bayer Launches New Contraceptive As Yaz Lawsuits Grow

The Drug Risk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
DrugRisk Dangerous Drugs
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism and believes it may be due to taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

Dallas, TX (PRWEB) December 11, 2012

Bayer announced this month that it had completed the approval process in Europe to launch its new Jaydess long-term contraceptive device. The device, which is designed to prevent pregnancy for up to three years, could also be approved soon in the U.S.*

The news comes as Bayer continues to settle lawsuits claiming its Yaz and Yasmin birth control drugs caused blood clot injuries. The German company’s latest financial report indicates it has settled approximately 3,500 Yaz cases so far at a total cost of nearly $750 million, or an average of approximately $214,000 per case.**

The company also confirmed they are only settling claims involving blood clot injuries, such as deep vein thrombosis and pulmonary embolism.

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

In October, the American College of Obstetricians and Gynecologists renewed warnings that birth control pills containing drospirenone such as Yaz and Yasmin may have a higher risk of causing blood clots.***

On October 25, 2011, the British Medical Journal published a study from the University of Copenhagen linking the hormone in Yaz to blood clots. On October 27, 2011, the FDA also released a study entitled "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints" showing drugs like Yaz could increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.

To handle the volume of claims, Yaz lawsuits were consolidated to a special federal Multi-District Litigation court in Illinois. The formal case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism and believes it may be due to taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

The Drug Risk Resource Center cautions that victims should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*foxbusiness.com/news/2012/12/05/bayer-gets-eu-green-light-to-market-jaydess-contraceptive/**Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012***Chicago Tribune October 24, 2012, “Newer Pill has low blood clot risk: ob-gyn group”


Contact